HOME >> BIOLOGY >> NEWS
Equine cloning may shed light on human cancer causes

mong horses is so low.

In July 2001, however, the team supplemented the amount of calcium in the implanted clones. "We increased the calcium in the medium holding the embryos and saw a seven-fold increase in our week two pregnancy rates," Woods said. "We produced 19 pregnancies; the first baby has been born, and two more pregnancies are in the advanced stages."

The team concluded that the increase in calcium within the implanted clone cells directly impacted the speed of cell division. Understanding the role of calcium in equine cell activity was a direct result of work conducted by Cancer2. Cancer2 gifted the intellectual property to UI.

According to existing research, the amount of intracellular calcium is higher than normal in humans with metastasizing cancer. According to Woods' research, the amount of intracellular calcium is below normal in horses. Within Cancer2, Woods and his team have discovered a chemical that suppresses intracellular calcium. Abnormally high intracellular calcium is a root cause of abnormally high cell activity in aged humans.

"There are electrifying similarities between cancer metastasis and embryo division," said Woods. He said he is working toward critical testing of the effects of deficiencies in the suppressor in human clinical trials. "We've identified a suppressor of intracellular calcium and believe its deficiency is the root cause of abnormally high intracellular calcium."

Woods established the Northwest Equine Reproduction Laboratory on the UI campus in 1986. He had come full circle, having completed pre-veterinary courses at the UI in 1974. A few years later, he earned the D.V.M. degree from Colorado State University.

Woods returned to the Northwest briefly to practice veterinary medicine then moved east to complete a residency in large animal reproduction at the University of Pennsylvania under R. M. Kenney. Next, at the University of Wisconsin, he became a student of O. J. Ginther, and complete
'"/>

Contact: Kathy Barnard
kbarnard@uidaho.edu
208-885-6291
University of Idaho
29-May-2003


Page: 1 2 3

Related biology news :

1. Equine clonings triple play sheds light on calcium, cell signaling, human disease
2. Malignant cancer cells generate mice through cloning
3. Stem-cell research and reproductive cloning laws should be separate
4. Therapeutic cloning no longer a dream, says scientist who produced first cloned embryonic stem cell
5. Why does cloning create abnormalities? Scientists take a step towards finding out
6. Therapeutic cloning may be permitted at Newcastle University
7. Landmark conference for United Nations on human cloning and stem cell research
8. Scientists develop new cloning technique that dramatically shortens the search for genes
9. Advances in equine cloning may aid insight into human diseases
10. International scientific body calls for ban on human reproductive cloning
11. Research shows therapeutic cloning can cure Parkinsons-like disease in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Equine cloning may shed light human cancer causes

(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce ... Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center ... come from and how agriculture impacts their daily lives. This unique exhibit also features ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: